A conserved 37 kDa outer membrane protein of Edwardsiella tarda is an effective vaccine candidate.

Vaccine

Department of Aquaculture, Fish Disease Laboratory, Faculty of Agriculture, Research Institute of Molecular Genetics, Kochi University, Nankoku, Kochi 783-8502, Japan.

Published: September 2004

An effective vaccine against Edwardsiella tarda has not been reported, one of main reasons is the variation in its serotypes. This study aimed to develop an effective vaccine against different serotypes of E. tarda. A conserved 37 kDa outer membrane protein (OMP) of E. tarda was obtained by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). It showed comprising several proteins by two-dimensional (2D) PAGE analysis and showed a high similarity to glyceraldehyde-3-phosphate dehydrogenase by N-terminal amino acid sequence analysis. Japanese flounder (Paralichthys olivaceus) vaccinated with the 37 kDa OMP was significantly protected against the infections by different serotypes of E. tarda. A specific antibody was also detected by using ELISA. This study suggests that the 37 kDa OMP is an effective potent vaccine candidate against different serotypes of E. tarda.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2004.02.026DOI Listing

Publication Analysis

Top Keywords

effective vaccine
12
serotypes tarda
12
conserved kda
8
kda outer
8
outer membrane
8
membrane protein
8
edwardsiella tarda
8
vaccine candidate
8
kda omp
8
tarda
6

Similar Publications

India's National COVID Vaccination Program recommended vaccination of children ages 6-12 years in April 2022. This study assessed vaccine acceptance among mothers to better understand potential barriers and facilitators of national acceptance of pediatric coronavirus disease 2019 (COVID-19) vaccination. Qualitative data were collected through three focus group discussions (FGDs) with mothers who had children younger than 12 years of age; FGD-1 was composed of mothers who worked at a tertiary medical center in India, whereas FGD-2 and FGD-3 were composed of mothers who sought care at urban and rural community health centers.

View Article and Find Full Text PDF

Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly hepatocellular carcinoma (HCC) and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenges in identifying at-risk patients.

View Article and Find Full Text PDF

Implementation of a data-driven quality improvement program in primary care for patients with coronary heart disease: a mixed methods evaluation of acceptability, satisfaction, barriers and enablers.

Aust J Prim Health

January 2025

School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; and The George Institute for Global Health, University of New South Wales, Barangaroo, NSW, Australia.

Background The study aimed to understand the acceptability, satisfaction, uptake, utility and feasibility of a quality improvement (QI) intervention to improve care for coronary heart disease (CHD) patients in Australian primary care practices and identify barriers and enablers, including the impact of COVID-19. Methods Within the QUality improvement for Effectiveness of care for people Living with heart disease (QUEL) study, 26 Australian primary care practices, supported by five Primary Health Networks (PHN) participated in a 1-year QI intervention (November 2019 - November 2020). Data were collected from practices and PHNs staff via surveys and semi-structured interviews.

View Article and Find Full Text PDF

The persistent emergence of COVID-19 variants and recurrent waves of infection worldwide underscores the urgent need for vaccines that effectively reduce viral transmission and prevent infections. Current intramuscular (IM) COVID-19 vaccines inadequately protect the upper respiratory mucosa. In response, we have developed a nonadjuvanted, interferon-armed SARS-CoV-2 fusion protein vaccine with IM priming and intranasal (IN) boost sequential immunization.

View Article and Find Full Text PDF

[Vaccination and cardiovascular diseases].

Herz

January 2025

Klinik für Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Str. 1, 66421, Homburg/Saar, Deutschland.

Respiratory tract infections with influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and respiratory syncytial (RS) viruses and pneumococci as well as endogenous reactivation of varicella zoster viruses presenting as herpes zoster, are associated with adverse cardiovascular outcomes, such as myocardial infarction or hospitalization for heart failure. Effective prevention of these events, particularly through influenza and pneumococcal vaccination, is well established and cost-effective. Despite guideline recommendations to vaccinate older patients and people at risk, vaccination rates in these population groups remain suboptimal and below average in international comparison.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!